Iterum Therapeutics plc (NASDAQ:ITRM) Sees Significant Decline in Short Interest

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a decrease of 14.6% from the February 13th total of 1,850,000 shares. Currently, 4.7% of the shares of the stock are sold short. Based on an average daily volume of 783,000 shares, the short-interest ratio is presently 2.0 days.

Iterum Therapeutics Stock Up 5.5 %

NASDAQ:ITRM opened at $1.45 on Thursday. Iterum Therapeutics has a 12-month low of $0.81 and a 12-month high of $3.02. The firm has a market capitalization of $50.14 million, a PE ratio of -1.11 and a beta of 2.44. The firm has a 50-day moving average price of $1.47 and a 200 day moving average price of $1.48.

Institutional Trading of Iterum Therapeutics

Several large investors have recently added to or reduced their stakes in ITRM. Renaissance Technologies LLC bought a new stake in Iterum Therapeutics during the fourth quarter worth about $777,000. XTX Topco Ltd bought a new stake in shares of Iterum Therapeutics during the third quarter valued at approximately $36,000. Apollon Financial LLC grew its stake in shares of Iterum Therapeutics by 11.3% during the fourth quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock valued at $443,000 after purchasing an additional 25,500 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Iterum Therapeutics during the fourth quarter valued at approximately $45,000. Finally, Citadel Advisors LLC bought a new stake in shares of Iterum Therapeutics during the fourth quarter valued at approximately $38,000. 9.21% of the stock is owned by institutional investors.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.